Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

Novavax (NVAX) filed a regulatory application to the EMA, which seeks to update its protein-based COVID19 vaccine for the 2024/2025 vaccination campaign. This submission is in line with the EMA's guidance issued on Apr 30, which advised COVID-19 vaccine manufacturers like Moderna (MRNA) , Novavax, and Pfizer (PFE) to update their respective COVID-19 vaccines to target the JN.1 variant. Year to date, the stock has skyrocketed 192.1% against the industry's 4.1% fall. Image Source: Zacks Investment Research Un ...